Evidence map›Paper›PMID 33316130›Full record

ArticleCurrent protocols in immunology2020

A Comprehensive Experimental Guide to Studying Cross-Presentation in Dendritic Cells In Vitro.

Barzan A Sadiq, Ian Mantel, J Magarian Blander

Open access · greenAbstract read
In one paragraph

Article in Current protocols in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Quantitative nanoscale imaging shows peptide-MHC I complexes are monomeric and spatially regulated in human dendritic cells.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Cellular Assays to Monitor Antigen Cross-presentation In Vitro.Methods in molecular biology (Clifton, N.J.) · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Barzan A SadiqThe Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, New York.
Ian MantelThe Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, New York.
J Magarian BlanderThe Jill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, New York.
Cornell University · US

Funding

Toll-like receptor control of endocytic antigen cross-presentationR01AI170832 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Julie Magarian Blander · 2023 to 2026
$2.7M
Mobilizing TAP-independent CD8 T cells through non-canonical cross-presentationR01AI170897 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Julie Magarian Blander · 2023 to 2026
$2.7M
The Regulatory Control Mechanisms of Cross-presentation by Toll-like ReceptorsR01AI073899 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BLANDER, JULIE MAGARIAN · 2008 to 2012
$2.1M
Novel vita-vaccine formula combines safety of dead and efficacy of live vaccinesR01AI127658 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLANDER, JULIE MAGARIAN · 2016 to 2020
$2.1M
Non-Canonical Cross-presentation in Dendritic Cells Upon TAP BlockadeR01AI123284 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLANDER, JULIE MAGARIAN · 2016 to 2020
$2.1M
Role of apoptosis in the intestinal epithelium during homeostasis and diseaseR01DK111862 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLANDER, JULIE MAGARIAN · 2017 to 2020
$1.5M
Innate and Adaptive Immune Consequences of NecroptosisR21AI154294 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLANDER, JULIE MAGARIAN · 2020 to 2021
$466k
Toll-like Receptor Control of MHC Class I EndocytosisR21AI159772 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI BLANDER, JULIE MAGARIAN · 2022 to 2023
$466k
The Regulatory Control Mechanisms of Cross-presentation by Toll-like ReceptorsR56AI073899 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BLANDER, JULIE MAGARIAN · 2007 to 2007
$424k
NIAID NIH HHS R01 AI073899NIAID NIH HHS R01 AI123284NIAID NIH HHS R01 AI127658NIAID NIH HHS R01 AI170832NIAID NIH HHS R01 AI170897NIAID NIH HHS R21 AI154294NIAID NIH HHS R21 AI159772NIAID NIH HHS R56 AI073899NIDDK NIH HHS R01 DK111862
6 · The paper itself

Abstract

Cross-presentation was first observed serendipitously in the 1970s. The importance of it was quickly realized and subsequently attracted great attention from immunologists. Since then, our knowledge of the ability of certain antigen presenting cells to internalize, process, and load exogenous antigens onto MHC-I molecules to cross-prime CD8

Indexed as

AnimalsBone Marrow CellsCD8-Positive T-LymphocytesCell Culture TechniquesCell DifferentiationCell ProliferationCross-PrimingDendritic CellsHumansLymphocyte ActivationMiceMicrospheresCD8+ T cellcross-presentationcross-primingDCdendritic cellsMHC-I

Identifiers

PMID33316130
PMCPMC9060150
OpenAlexW3111028888

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.